Moderna Inc (MRNA) USD0.0001

Sell:$27.24Buy:$27.25$0.50 (1.83%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$27.24
Buy:$27.25
Change:$0.50 (1.83%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$27.24
Buy:$27.25
Change:$0.50 (1.83%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Key people

Stephen Hoge
President
Stephane Bancel
Chief Executive Officer, Director
James M. Mock
Chief Financial Officer
Jerh Collins
Chief Technical Operations and Quality Officer
Tracey Franklin
Chief People and Digital Technology Officer
Rose Loughlin
Executive Vice President - Research
Kate Cronin
Chief Brand Officer
Jacqueline Miller
Chief Medical Officer
Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Noubar B. Afeyan
Non-Executive Independent Chairman of the Board, Co-Founder
Sandra J. Horning
Independent Director
Abbas Hussain
Independent Director
Elizabeth G. Nabel
Independent Director
Francois Nader
Independent Director
Click to see more

Key facts

  • EPIC
    MRNA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US60770K1079
  • Market cap
    $10.26bn
  • Employees
    5,800
  • Shares in issue
    386.62m
  • Exchange
    NASDAQ
  • Index
    S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.